ESMO: AstraZeneca's Imfinzi extends life in prostate cancer type. Will FDA push back on its perioperative trial design?
Fierce Pharma
SEPTEMBER 14, 2024
AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive bladder cancer (MIBC). | AstraZeneca’s detailed data show exactly how Imfinzi became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive bladder cancer. But the win came from a perioperative regimen, a trial design that’s been criticized by the FDA in lung cancer.
Let's personalize your content